Boston Scientific Corporation

Fundamentals8.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Profitability Strength
  • Cash Flow Quality
  • Liquidity Watch

AI
AI Summary

6.0

BSX has shifted from a clean mid-teens growth story to a near-term reset, with WATCHMAN softness and U.S. EP competition now the key swing factors, so the stock is only attractive if upcoming updates confirm this is temporary rather than the start of a more durable share-loss phase.

ExecutionRisk
Watchman
CashFlow

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Profitability Strength
  • Cash Flow Quality
  • Liquidity Watch

BSX shows strong profitability and cash generation with moderate leverage, but tighter liquidity and a heavy intangible-asset balance temper the story, especially at a still-premium valuation.

StrongMargins
LiquidityRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher highs
  • Dip buying
  • Stretched momentum

BSX remains in a strong short-term uptrend, but after an ~18% rise over the last month it looks overbought, so bulls should watch $49.30 support and $51.83 resistance for signs of either continuation or a pullback.

Bullish
Overbought
Support Level: $49.30-$49.31
Resistance Level: $51.69-$51.83

~18% rally over the last month with overbought momentum

Sentiment & News

6.0

Key News Insights:

  • Q2 Beat
  • WATCHMAN Slowdown
  • Valuation Reset

Boston Scientific beat Q2 expectations and still shows solid core growth, but guidance cuts tied to WATCHMAN and U.S. EP competition are pressuring sentiment despite valuation support.

Growth
Headwinds

The stock may stay range-bound near term as investors weigh strong underlying growth against segment-specific headwinds and a lowered outlook